cat no | ioEA1006
A rapidly maturing, consistent and scalable isogenic system to study amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
ioGlutamatergic Neurons TDP‑43 M337V/WT are opti‑ox™ precision reprogrammed glutamatergic neurons carrying a genetically engineered heterozygous M337V mutation in the TARDBP gene, encoding TAR DNA binding protein 43 (TDP‑43).
Related disease model cells are available with a homozygous TDP‑43 M337V/M337V mutation, and both can be used alongside their genetically matched (isogenic) control, ioGlutamatergic Neurons™.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Click here for bulk request
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to investigate the impact of mutant TDP‑43 protein on disease progression.
Scalable
Industrial scale quantities are available with industry-leading seeding densities, and at a price point that allows the cells to be used from research to high throughput screening.
Quick
The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
ioGlutamatergic Neurons TDP‑43 M337V/WT express neuron-specific markers with protein expression highly reminiscent to the isogenic control
ioGlutamatergic Neurons TDP‑43 M337V/WT form structural neuronal networks by day 11
ioGlutamatergic Neurons TDP‑43 M337V/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following reprogramming
Disease-related TARDBP is expressed in ioGlutamatergic Neurons TDP‑43 M337V/WT following reprogramming
Oosterveen, et al
bit.bio & Charles River Laboratories
2023
Madeleine Garrett | Field Application Specialist | bit.bio
Oosterveen et al
bit.bio
2022
Ritsma, et al
Charles River Laboratories & bit.bio
2022
Read this blog to find out how experts from across academia and industry are approaching the challenges of reproducibility of in vitro cell models as well as potential solutions.
Further your disease research by pairing our wild type Cells with isogenic disease models.